Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Oct 14, 2016; 22(38): 8447-8458
Published online Oct 14, 2016. doi: 10.3748/wjg.v22.i38.8447
Table 1 Interferon-based antiviral treatment in hepatitis C virus-infected patients with low-grade non-Hodgkin lymphomas
YearNo. of patientsDiagnosisGenotypesCryoglobulinemiaAntiviral treatmentVirologic responseNHL response
Bauduer[35]19961MZL of MALT (oral cavity)NA-α-IFN11 PR
Caramaschi et al[36]19991MZL of MALT (salivary glands)NA-α-IFNNA1 CR
Moccia et al[37]19993SMZLNA-α-IFNNA2 CR
Patriarca et al[38]20011LPL2a/2c-α-IFN11 CR
Hermine et al[30]20029SLVLNA6α-IFN77 CR
Casato et al[39]20021Leukemic MZLNA1α-IFNDecreased HCV-RNA1 CR
Pitini et al[63]20042SMZLNA-α-IFN22 CR
Tursi et al[64]200416MZL of MALT (stomach)NA-α-IFN-2b + RBV11/1616 CR
Kelaidi et al[41]20048SMZL (n = 4)3a (n = 1), 5a (n = 1)8α-IFN-2b + RBV5 SVR, 2 PR5 CR
Disseminated MZL (n = 1)-
Leukemic MZL (n = 1)1b
MZL of MALT (n = 2) (1 duodenus; 1 ileus)4c/4d
Vallisa et al[42]200513SMZL (n = 4)1b (n = 2), 2b (n = 1)5Peg-IFN + RBV7 SVR, 1 PR7 CR, 2 PR
NMZL (n = 2)2a/2c (n = 1), 1b (n = 1)
MZL of MALT (n = 2)1b (n = 2)
FL (n = 1)2a
LPL (n = 4)2a/2c (n = 1), 1b (n = 1),
na (n = 2)
Svoboda et al[65]20051MZL of MALT (salivary gland, liver)2b-Peg-IFN + RBV1CR
Saadoun et al[24]200518SLVL1 (n = 7)18α-IFN (+ RBV in 10)14 CR, 4 PR14 CR, 4 PR
2 (n = 4)
3 (n = 1)
4 (n = 1)
Paulli et al[25]20092Subcutaneous MZL of MALT2a/2c, 2b2Peg-IFN + RBV2 CR1 CR, 1 PR
Mazzaro et al[43]2009181 SLVL1b (n = 11)13α -IFN + RBV (n = 8)9 SVR9 CR, 4 PR
1 FL2a/2c (n = 7)Peg-IFN + RBV (n = 10)
16 LPL
Oda et al[66]20101B-NHL (liver)2a-Peg-IFN + RBVSVRCR
Pellicelli et al[67]201193 SMZL1b (n = 2)4Peg-IFN + RBV7 SVR5 CR, 2 PR
3 MZL of MALT2 (n = 2)
1 NMZL2a (n = 2)
2 FL2a/2c (n = 3)
Mauro et al[68]20121LPL1b1Peg-IFN + RBV (2nd line)SVRCR
Arcaini et al[45]201410023 SMZL1 (n = 37)34α-IFN (n = 33) (+ RBV in 26)80% SVR44% CR, 33% PR
(1st-line)12 NMZL2 (n = 52)Peg-IFN (n = 67) (+ RBV in 57)
25 MZL of MALT3 (n = 5)
7 LPL5 (n = 1)
5 FLNA (n = 5)
1 SLL
27 Low-grade NHL NOS
3412 SMZL1 (n = 15)10α-IFN (n = 14) (+ RBV in 10)67% SVR56% CR, 29% PR
(2nd-line)2 NMZL2 (n = 13)Peg-IFN (n = 20) (+ RBV in 15)
6 MZL of MALT3 (n = 2)
2 LPL5 (n = 1)
7 FLNA (n = 4)
3 SLL
2 Low-grade NHL NOS
Michot et al[28]20151414 MZLNANAPeg-IFN + RBV (n = 12)79% SVR (AT alone)57% CR, 21% PR
(AT alone)
8 (At + Rituximab)8 MZLNANAPegIFN + RBV + 4 Rituximab (n = 8)NA (AT + Rituximab)38% CR, 62% PR
Table 2 Direct-acting antiviral agents-based antiviral treatment in hepatitis C virus-infected patients with low-grade non-Hodgkin lymphomas
YearNo. of patientsDiagnosisGenotypesCryoglobulinemiaAntiviral treatmentVirologic responseNHL response
Rossotti et al[58]20151SMZL1bYes (type II MC)FDV + DLV + RBV (16 w)SVRPR
Sultanik et al[59]20151MALT MZL (breast, humeral shaft, cervical lymph node)3aYes (type II MC)SOF + RBV (4 w), then SOF + DCV (12 w)SVRCR
(ongoing at 6 m)
Carrier et al[60]201531 Leukemic MZL43 (type II MC)SOF - SIM3 SVRPR
1 MALT MZL (kidney)1bSOF - SIM + 4 RtxCR
1 SMZL1bSOF - DCVCR
Lim et al[61]20151SMZL2NoSOF + RBV (12 w)SVRCR
(ongoing at 17 m)
Arcaini et al[62]2015209 SMZL1 (n = 13)10 (50%)various19 SVR4 CR, 2 PR, 2 SD 1 PD
1 NMZL (Nodal)2 (n = 3)SOF-based regimens1 CR
5 MALT MZL3 (n = 3)2 CR, 1 PR, 2 PD
2 Leukemic MZL4 (n = 1)(+ 4 Rtx in 1 pts)1 CR, 1 PR
2 CLL2 SD
1 LPL1 SD